Understanding how cells respond differently to the Erk signaling pathway
Characterizing the interpretation and generation of Erk signaling dynamics using high-throughput genetics
['FUNDING_FELLOWSHIP'] · PRINCETON UNIVERSITY · NIH-10901239
This study is looking at how cells make different choices using a special signaling pathway, which is important for things like growth and cancer, and it’s designed for anyone interested in understanding how cells behave differently even when they start off the same.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PRINCETON UNIVERSITY (nih funded) |
| Locations | 1 site (Princeton, UNITED STATES) |
| Trial ID | NIH-10901239 on ClinicalTrials.gov |
What this research studies
This research investigates how cells use the Erk signaling pathway to make different decisions, which is important for processes like development and cancer. By employing a novel biosensor called READer, the study aims to track and analyze the dynamics of Erk signaling in real-time. The researchers will utilize genomic methods to identify the molecular factors that contribute to the varied responses of cells to Erk activation. This approach allows for a deeper understanding of how cells can exhibit distinct behaviors despite having similar initial conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that may involve heterogeneous cell responses or drug resistance.
Not a fit: Patients with conditions unrelated to cancer or those not exhibiting variability in cell signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for targeting cancer cells that exhibit drug resistance.
How similar studies have performed: Previous research has shown promise in understanding cell signaling dynamics, making this approach both innovative and grounded in prior successes.
Where this research is happening
Princeton, UNITED STATES
- PRINCETON UNIVERSITY — Princeton, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SOLLEY, SABRINA — PRINCETON UNIVERSITY
- Study coordinator: SOLLEY, SABRINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancers